Skip to main content

Efficiently networking European neurodegeneration research


Start Date
End Date
Total Funding
€ 2 353 125
Funding Programme
European Countries Involved

IMI’s growing neurodegenerative disorders (ND) portfolio is to get a new, dynamic platform – NEURONET – that will make it easier for the many projects to exploit synergies and connect the resources and needs of the different projects. NEURONET aims to be a key enabler and mediator across the portfolio, assisting in identifying gaps, multiplying impacts, enhancing visibility and ensuring coordination with related initiatives in Europe and worldwide. The mapping of ND actions and initiatives is among NEURONET’s objectives, as is providing coordination and support to the individual IMI projects, management support to the whole programme, and the identification and dissemination of best practices and learnings. Designed to take a different approach to typical Coordination and Support Actions (CSAs), NEURONET hopes to help IMI’s ND projects to create a platform for the efficient collaboration of current and future IMI ND projects, thus helping them to make progress and deliver results that will benefit the millions of people who live with neurodegenerative diseases.

Project partners

Synapse Research Management Partners Sl
National Institute For Health And Care Excellence
Alzheimer Europe
Janssen Pharmaceutica Nv
Eli Lilly And Company Limited
F. Hoffmann-La Roche Ag
Takeda Development Centre Europe Ltd
Sanofi-Aventis Recherche & Developpement
Parkinson'S Disease Society Of Theunited Kingdom Lbg

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).